Dyson Perrins-Eli Lilly

Title

Dyson Perrins-Eli Lilly

Shelfmark

MS. Abraham 83/C.625-C.642

Summary

C.625-C.632: Dyson Perrins Laboratory (Oxford), 1971, 1978-1991. The 1970s and 1980s saw various collaborative projects on the biosynthesis of penicillins and cephalosporins involving the Dyson Perrins Laboratory, the Sir William Dunn School of Pathology and Eli Lilly (see C.633-C.881).

Correspondence and papers: included is correspondence with Jack Baldwin regarding research on biosynthesis of penicillins and cephalosporins and related articles. Some correspondence relates to appointments to research and other posts, including refereeing. At C.628-C.630 are manuscript and typescript drafts of an article by Abraham and Baldwin 'The Biosynthesis of Penicillins and Cephalosporins', Natural Products Reports 5 (Royal Society of Chemistry), 1988, with correspondence regarding publication.

C.633-C.642: Eli Lilly and Company.

Eli Lilly signed an agreement with the NRDC in January 1959 for a research programme aimed at producing substances related to Cephalosporin C (including its nucleus). This project was unsuccessful, but in early 1960 the NRDC granted the company an option on a licence allowing it to research processes of converting Cephalosporin C to its nucleus (7-ACA). It was the only licensee to achieve a breakthrough in this area, paving the way for large-scale production of the nucleus. Eli Lilly introduced its first cephalosporin antibiotic in 1964. In the following years Eli Lilly funded collaborative research projects on the biosynthesis of penicillins and cephalosporins involving the Sir William Dunn School of Pathology and the Dyson Perrins Laboratory (see C.625-C.632).

Correspondence, 1954, 1957-1962. Some correspondence, 1957-1959, relates to the preparation of crude secretin.

Date

1954-1991

Language

English

Physical extent

18 folders